Patent ID: 11925694
Assignee: BIONTECH SE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  B  C  Y | IPC A  B  C

Claim 15:
16. A method of vaccinating by administering a pharmaceutical composition comprising an RNA, wherein said RNA comprises, from a 5′ to 3′ direction:
(i) a 5′-UTR that comprises a human alpha-globin 5′-UTR,
(ii) a nucleotide sequence that is at least 90% identical to SEQ ID NO: 9, wherein said nucleotide sequence:
(a) includes modified uridines in place of uridines; and
(b) encodes a SARS-CoV-2 Spike (S) polypeptide that is at least 95% identical to SEQ ID NO: 7 and is prefusion stabilized in that it includes at least one proline substitution at position(s) corresponding to position(s) 986 and/or 987 in SEQ ID NO: 7; and

(iii) a 3′-UTR that comprises a first sequence from the amino terminal enhancer of split (AES) messenger RNA and a second sequence from the mitochondrial encoded 12S ribosomal RNA.